Compared with the level of CXCL10 in BAL fluid, the expression of CXLC10 by persistent tumor cells was significantly decreased immediately after 1 day of erlotinib treatment, but it gradually increased with erlotinib treatment (Figure 5B,C). Here, CXCL10 is linked to neoplasm.